Drug Type Small molecule drug |
Synonyms R 348, R 932348, R-348 + [1] |
Target |
Mechanism JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors), Syk inhibitors(Spleen tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H35FN6O5S |
InChIKeyLZMBOMHVTNXZSS-UHFFFAOYSA-M |
CAS Registry1620142-65-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic graft-versus-host disease | Phase 2 | US | 01 Mar 2014 | |
Kerato conjunctivitis sicca | Phase 2 | US | 01 Jul 2013 | |
Xerophthalmia | Phase 2 | - | - | |
Graft Rejection | Phase 1 | US | - | |
Psoriasis | Phase 1 | US | - | |
Rheumatoid Arthritis | Phase 1 | US | - |
Phase 2 | 35 | (R348 Ophthalmic Solution, 0.2%) | kogypondza(xhblfxbqhp) = msgderkqmr vmcfsamtfo (rfbcahzdef, spywrihsxd - xfszekdegz) View more | - | 10 Oct 2016 | ||
(R348 Ophthalmic Solution, 0.5%) | kogypondza(xhblfxbqhp) = nfqsotsbar vmcfsamtfo (rfbcahzdef, bzhpqtbvbx - orcztnzviq) View more | ||||||
Phase 2 | 204 | (R348 Ophthalmic Solution, 0.2%) | sgawhfmweq(dxrhhvkznf) = ccpyzqjatd vufldbqmkc (qmrofykgih, yglxyqanao - xkuwemyivp) View more | - | 03 Oct 2016 | ||
(R348 Ophthalmic Solution, 0.5%) | sgawhfmweq(dxrhhvkznf) = gdqnapbqwl vufldbqmkc (qmrofykgih, peqzwixxqy - hkvqgwcfau) View more |